Newborn Screening for Cystic Fibrosis: A Paradigm for Public Health Genetics211 Policy Development. Proceedings of a Workshop. Held in Atlanta, Georgia in 211 January 1997. Morbidity and Mortality Weekly Report, Vol. 46, No. RR-16, December 211 12, 1997

摘要

Cystic fibrosis (CF) is a genetic disease that can be detected in newborn infants211u001eby immunotrypsinogen testing. The sensitivity and specificity of such testing can 211u001enow be improved as a result of the recent discovery of the Cystic Fibrosis 211u001eTransmembrane Conductance Regulatory (CFTR) gene. Although limited CF screening 211u001efor newborns has been used since the 1980s, the clinical, social, and economic 211u001eoutcomes of population-based screening are controversial. During January 1997, a 211u001eworkshop was convened at CDC in Atlanta, Georgia to discuss the benefits and 211u001erisks associated with screening newborns for CF and to develop public health 211u001epolicy concerning such screening. The workshop planning committee comprised 211u001erepresentatives from CDC, the Cystic Fibrosis Foundation, the National Institutes 211u001eof Health, and the University of Wisconsin. Experts in the fields of CF, public 211u001ehealth, the screening of newborns, and economics also contributed to discussions.